23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia

The 23andMe PGS Genetic Health Risk Test for Hereditary Thrombophilia aims to identify Factor V Leiden and Prothrombin G20210A variants, associated with increased blood clot risk, in individuals of European ancestry using SNP genotyping of saliva samples. Its science leverages validated microarray technology to detect these DNA markers, providing direct-to-consumer genetic risk information intended to supplement, not replace, professional medical advice.

The 23andMe PGS Genetic Health Risk Test for Hereditary Thrombophilia is designed to analyze an individual's saliva sample for two specific DNA variants: Factor V Leiden (F5) and Prothrombin G20210A (F2). These genetic markers are known to be associated with an elevated risk of developing blood clots, a condition known as hereditary thrombophilia. The primary purpose of this direct-to-consumer test is to inform users, particularly those of European ancestry, about their carrier status for these mutations, thereby enhancing their awareness of personal genetic predispositions and encouraging them to consult with healthcare professionals if a variant is detected for further evaluation and guidance. The test employs SNP genotyping utilizing validated microarray technology to identify the presence of the F5 and F2 variants, ensuring clinical accuracy standards for these specific genetic markers. As a direct-to-consumer offering, the results are presented in an accessible, lay-friendly format, accompanied by necessary disclaimers. It is crucial to understand that this test serves as a supplementary tool for risk awareness and is not intended to substitute a comprehensive clinical risk assessment or diagnostic procedures conducted by a qualified healthcare provider.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What is the penetrance of Factor V Leiden and Prothrombin G20210A in individuals of European ancestry who test positive, and how does this compare to other ethnicities not explicitly targeted by this specific test?; Beyond European ancestry, what is the rationale for not including other common thrombophilic mutations or populations where these specific F5 and F2 variants also have significant prevalence?; How does the 'lay-friendly' reporting of results ensure appropriate understanding and action without causing undue anxiety or misinterpretation of risk, particularly regarding the absolute versus relative risk increase?; What are the specific performance characteristics (sensitivity, specificity, positive predictive value, negative predictive value) of the SNP genotyping and microarray technology used for detecting F5 and F2 variants in the context of a direct-to-consumer setting?; What evidence exists regarding the impact of this DTC test on subsequent patient behavior, specifically in terms of seeking appropriate medical consultation and adherence to preventative measures if a variant is identified?